Loading…
Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis
Due to the increasing emergence of antibiotic resistance in Enterococcus faecalis (E. faecalis), it indicated as potentially opportunistic pathogen causing various healthcare-associated and life-threatening diseases around the world. The aim of this meta-analysis was to evaluate the weighted pooled...
Saved in:
Published in: | Annals of clinical microbiology and antimicrobials 2024-08, Vol.23 (1), p.80-16 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 16 |
container_issue | 1 |
container_start_page | 80 |
container_title | Annals of clinical microbiology and antimicrobials |
container_volume | 23 |
creator | Guan, Lingbo Beig, Masoumeh Wang, Lina Navidifar, Tahereh Moradi, Samaneh Motallebi Tabaei, Faezeh Teymouri, Zahra Abedi Moghadam, Mahya Sedighi, Mansour |
description | Due to the increasing emergence of antibiotic resistance in Enterococcus faecalis (E. faecalis), it indicated as potentially opportunistic pathogen causing various healthcare-associated and life-threatening diseases around the world.
The aim of this meta-analysis was to evaluate the weighted pooled resistance rates in clinical E. faecalis isolates based on over time, areas, antimicrobial susceptibility testing (AST), and infection source.
We searched the studies in PubMed, Scopus, and Web of Science (November 30, 2022). All statistical analyses were carried out using the statistical package R.
The analysis encompassed a total of 74 studies conducted in 28 countries. According to the meta-regression, the chloramphenicol, fosfomycin, imipenem, linezolid, minocycline, norfloxacin, quinupristin-dalfopristin, and tetracycline resistance rate increased over time. Analysis revealed statistically significant differences in antibiotic resistance rates for ampicillin, chloramphenicol, erythromycin, gentamicin, penicillin, rifampicin, teicoplanin, tetracycline, and vancomycin across various countries.
Globally, the prevalence of drug resistant E. faecalis strains are on the increase over time. Daptomycin and tigecycline can be an effective agent for the treatment of clinical E. faecalis infections. Considering the low prevalence of antibiotic resistance in continents of Europe and Australia, it is suggested to take advantage of their preventive strategies in order to obtain efficient results in other places with high prevalence of resistance. |
doi_str_mv | 10.1186/s12941-024-00728-w |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4bfa0dd6b27044e8af35bd2e63964d2c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A808371459</galeid><doaj_id>oai_doaj_org_article_4bfa0dd6b27044e8af35bd2e63964d2c</doaj_id><sourcerecordid>A808371459</sourcerecordid><originalsourceid>FETCH-LOGICAL-d330t-34cca3bf019cb54f1efd7f4e3ce486f42ae21ead3c3b0b6c5f55ea5b7fdde76e3</originalsourceid><addsrcrecordid>eNptkk1rFTEUhgdRbK3-ARcy4MbN1HzNZOJGSqm1UHCj63CSnFxTMkmd5Lbcf9_ordILkkXCe57zcELSdW8pOaV0nj4WypSgA2FiIESyebh_1h1TIaeBSEqfPzkfda9KuSGEETLJl90RV3RmRLHjbncZs4HYlwp1W_rse0g1LMGu2YSWr1hCqyWLfUi9jSEF2-KLVHHNNlvbmjxgy0LpQ8kRKpZPfdmVigvUYJvhLuB907p-wQoDJIi7Jn3dvfAQC7553E-6H18uvp9_Ha6_XV6dn10PjnNSBy6sBW48ocqaUXiK3kkvkFsU8-QFA2QUwXHLDTGTHf04IoxGeudQTshPuqu912W40bdrWGDd6QxB_wnyutGwtkEjamE8EOcmwyQRAmfwfDSO4cTVJByzzfV577rdmgWdxVRXiAfSw0oKP_Um32lKuRCK82b48GhY868tlqqXUCzGCAnztmhOlKRCUSYb-n6PbqDNFpLPTWl_4_psJjNv3Kgadfofqi2H7RVzQh9aftDw7ukd_g3_90_wBz4OvVQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097149127</pqid></control><display><type>article</type><title>Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis</title><source>PubMed Central(OpenAccess)</source><source>ProQuest - Publicly Available Content Database</source><creator>Guan, Lingbo ; Beig, Masoumeh ; Wang, Lina ; Navidifar, Tahereh ; Moradi, Samaneh ; Motallebi Tabaei, Faezeh ; Teymouri, Zahra ; Abedi Moghadam, Mahya ; Sedighi, Mansour</creator><creatorcontrib>Guan, Lingbo ; Beig, Masoumeh ; Wang, Lina ; Navidifar, Tahereh ; Moradi, Samaneh ; Motallebi Tabaei, Faezeh ; Teymouri, Zahra ; Abedi Moghadam, Mahya ; Sedighi, Mansour</creatorcontrib><description>Due to the increasing emergence of antibiotic resistance in Enterococcus faecalis (E. faecalis), it indicated as potentially opportunistic pathogen causing various healthcare-associated and life-threatening diseases around the world.
The aim of this meta-analysis was to evaluate the weighted pooled resistance rates in clinical E. faecalis isolates based on over time, areas, antimicrobial susceptibility testing (AST), and infection source.
We searched the studies in PubMed, Scopus, and Web of Science (November 30, 2022). All statistical analyses were carried out using the statistical package R.
The analysis encompassed a total of 74 studies conducted in 28 countries. According to the meta-regression, the chloramphenicol, fosfomycin, imipenem, linezolid, minocycline, norfloxacin, quinupristin-dalfopristin, and tetracycline resistance rate increased over time. Analysis revealed statistically significant differences in antibiotic resistance rates for ampicillin, chloramphenicol, erythromycin, gentamicin, penicillin, rifampicin, teicoplanin, tetracycline, and vancomycin across various countries.
Globally, the prevalence of drug resistant E. faecalis strains are on the increase over time. Daptomycin and tigecycline can be an effective agent for the treatment of clinical E. faecalis infections. Considering the low prevalence of antibiotic resistance in continents of Europe and Australia, it is suggested to take advantage of their preventive strategies in order to obtain efficient results in other places with high prevalence of resistance.</description><identifier>ISSN: 1476-0711</identifier><identifier>EISSN: 1476-0711</identifier><identifier>DOI: 10.1186/s12941-024-00728-w</identifier><identifier>PMID: 39182092</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antimicrobial resistance ; Care and treatment ; Clinical samples ; Complications and side effects ; Dosage and administration ; Drug resistance in microorganisms ; Drug Resistance, Bacterial ; Drug Resistance, Multiple, Bacterial ; Drug therapy ; Enterococcal infections ; Enterococcus faecalis ; Enterococcus faecalis - drug effects ; Global Health ; Gram-Positive Bacterial Infections - drug therapy ; Gram-Positive Bacterial Infections - epidemiology ; Gram-Positive Bacterial Infections - microbiology ; Hospital patients ; Humans ; Microbial Sensitivity Tests ; Patient outcomes ; Prevention ; Review ; Systematic review and meta-analysis</subject><ispartof>Annals of clinical microbiology and antimicrobials, 2024-08, Vol.23 (1), p.80-16</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344933/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344933/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39182092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guan, Lingbo</creatorcontrib><creatorcontrib>Beig, Masoumeh</creatorcontrib><creatorcontrib>Wang, Lina</creatorcontrib><creatorcontrib>Navidifar, Tahereh</creatorcontrib><creatorcontrib>Moradi, Samaneh</creatorcontrib><creatorcontrib>Motallebi Tabaei, Faezeh</creatorcontrib><creatorcontrib>Teymouri, Zahra</creatorcontrib><creatorcontrib>Abedi Moghadam, Mahya</creatorcontrib><creatorcontrib>Sedighi, Mansour</creatorcontrib><title>Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis</title><title>Annals of clinical microbiology and antimicrobials</title><addtitle>Ann Clin Microbiol Antimicrob</addtitle><description>Due to the increasing emergence of antibiotic resistance in Enterococcus faecalis (E. faecalis), it indicated as potentially opportunistic pathogen causing various healthcare-associated and life-threatening diseases around the world.
The aim of this meta-analysis was to evaluate the weighted pooled resistance rates in clinical E. faecalis isolates based on over time, areas, antimicrobial susceptibility testing (AST), and infection source.
We searched the studies in PubMed, Scopus, and Web of Science (November 30, 2022). All statistical analyses were carried out using the statistical package R.
The analysis encompassed a total of 74 studies conducted in 28 countries. According to the meta-regression, the chloramphenicol, fosfomycin, imipenem, linezolid, minocycline, norfloxacin, quinupristin-dalfopristin, and tetracycline resistance rate increased over time. Analysis revealed statistically significant differences in antibiotic resistance rates for ampicillin, chloramphenicol, erythromycin, gentamicin, penicillin, rifampicin, teicoplanin, tetracycline, and vancomycin across various countries.
Globally, the prevalence of drug resistant E. faecalis strains are on the increase over time. Daptomycin and tigecycline can be an effective agent for the treatment of clinical E. faecalis infections. Considering the low prevalence of antibiotic resistance in continents of Europe and Australia, it is suggested to take advantage of their preventive strategies in order to obtain efficient results in other places with high prevalence of resistance.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antimicrobial resistance</subject><subject>Care and treatment</subject><subject>Clinical samples</subject><subject>Complications and side effects</subject><subject>Dosage and administration</subject><subject>Drug resistance in microorganisms</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drug therapy</subject><subject>Enterococcal infections</subject><subject>Enterococcus faecalis</subject><subject>Enterococcus faecalis - drug effects</subject><subject>Global Health</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Gram-Positive Bacterial Infections - epidemiology</subject><subject>Gram-Positive Bacterial Infections - microbiology</subject><subject>Hospital patients</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Patient outcomes</subject><subject>Prevention</subject><subject>Review</subject><subject>Systematic review and meta-analysis</subject><issn>1476-0711</issn><issn>1476-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkk1rFTEUhgdRbK3-ARcy4MbN1HzNZOJGSqm1UHCj63CSnFxTMkmd5Lbcf9_ordILkkXCe57zcELSdW8pOaV0nj4WypSgA2FiIESyebh_1h1TIaeBSEqfPzkfda9KuSGEETLJl90RV3RmRLHjbncZs4HYlwp1W_rse0g1LMGu2YSWr1hCqyWLfUi9jSEF2-KLVHHNNlvbmjxgy0LpQ8kRKpZPfdmVigvUYJvhLuB907p-wQoDJIi7Jn3dvfAQC7553E-6H18uvp9_Ha6_XV6dn10PjnNSBy6sBW48ocqaUXiK3kkvkFsU8-QFA2QUwXHLDTGTHf04IoxGeudQTshPuqu912W40bdrWGDd6QxB_wnyutGwtkEjamE8EOcmwyQRAmfwfDSO4cTVJByzzfV577rdmgWdxVRXiAfSw0oKP_Um32lKuRCK82b48GhY868tlqqXUCzGCAnztmhOlKRCUSYb-n6PbqDNFpLPTWl_4_psJjNv3Kgadfofqi2H7RVzQh9aftDw7ukd_g3_90_wBz4OvVQ</recordid><startdate>20240824</startdate><enddate>20240824</enddate><creator>Guan, Lingbo</creator><creator>Beig, Masoumeh</creator><creator>Wang, Lina</creator><creator>Navidifar, Tahereh</creator><creator>Moradi, Samaneh</creator><creator>Motallebi Tabaei, Faezeh</creator><creator>Teymouri, Zahra</creator><creator>Abedi Moghadam, Mahya</creator><creator>Sedighi, Mansour</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240824</creationdate><title>Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis</title><author>Guan, Lingbo ; Beig, Masoumeh ; Wang, Lina ; Navidifar, Tahereh ; Moradi, Samaneh ; Motallebi Tabaei, Faezeh ; Teymouri, Zahra ; Abedi Moghadam, Mahya ; Sedighi, Mansour</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d330t-34cca3bf019cb54f1efd7f4e3ce486f42ae21ead3c3b0b6c5f55ea5b7fdde76e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antimicrobial resistance</topic><topic>Care and treatment</topic><topic>Clinical samples</topic><topic>Complications and side effects</topic><topic>Dosage and administration</topic><topic>Drug resistance in microorganisms</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drug therapy</topic><topic>Enterococcal infections</topic><topic>Enterococcus faecalis</topic><topic>Enterococcus faecalis - drug effects</topic><topic>Global Health</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Gram-Positive Bacterial Infections - epidemiology</topic><topic>Gram-Positive Bacterial Infections - microbiology</topic><topic>Hospital patients</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Patient outcomes</topic><topic>Prevention</topic><topic>Review</topic><topic>Systematic review and meta-analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guan, Lingbo</creatorcontrib><creatorcontrib>Beig, Masoumeh</creatorcontrib><creatorcontrib>Wang, Lina</creatorcontrib><creatorcontrib>Navidifar, Tahereh</creatorcontrib><creatorcontrib>Moradi, Samaneh</creatorcontrib><creatorcontrib>Motallebi Tabaei, Faezeh</creatorcontrib><creatorcontrib>Teymouri, Zahra</creatorcontrib><creatorcontrib>Abedi Moghadam, Mahya</creatorcontrib><creatorcontrib>Sedighi, Mansour</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Annals of clinical microbiology and antimicrobials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guan, Lingbo</au><au>Beig, Masoumeh</au><au>Wang, Lina</au><au>Navidifar, Tahereh</au><au>Moradi, Samaneh</au><au>Motallebi Tabaei, Faezeh</au><au>Teymouri, Zahra</au><au>Abedi Moghadam, Mahya</au><au>Sedighi, Mansour</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis</atitle><jtitle>Annals of clinical microbiology and antimicrobials</jtitle><addtitle>Ann Clin Microbiol Antimicrob</addtitle><date>2024-08-24</date><risdate>2024</risdate><volume>23</volume><issue>1</issue><spage>80</spage><epage>16</epage><pages>80-16</pages><issn>1476-0711</issn><eissn>1476-0711</eissn><abstract>Due to the increasing emergence of antibiotic resistance in Enterococcus faecalis (E. faecalis), it indicated as potentially opportunistic pathogen causing various healthcare-associated and life-threatening diseases around the world.
The aim of this meta-analysis was to evaluate the weighted pooled resistance rates in clinical E. faecalis isolates based on over time, areas, antimicrobial susceptibility testing (AST), and infection source.
We searched the studies in PubMed, Scopus, and Web of Science (November 30, 2022). All statistical analyses were carried out using the statistical package R.
The analysis encompassed a total of 74 studies conducted in 28 countries. According to the meta-regression, the chloramphenicol, fosfomycin, imipenem, linezolid, minocycline, norfloxacin, quinupristin-dalfopristin, and tetracycline resistance rate increased over time. Analysis revealed statistically significant differences in antibiotic resistance rates for ampicillin, chloramphenicol, erythromycin, gentamicin, penicillin, rifampicin, teicoplanin, tetracycline, and vancomycin across various countries.
Globally, the prevalence of drug resistant E. faecalis strains are on the increase over time. Daptomycin and tigecycline can be an effective agent for the treatment of clinical E. faecalis infections. Considering the low prevalence of antibiotic resistance in continents of Europe and Australia, it is suggested to take advantage of their preventive strategies in order to obtain efficient results in other places with high prevalence of resistance.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>39182092</pmid><doi>10.1186/s12941-024-00728-w</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1476-0711 |
ispartof | Annals of clinical microbiology and antimicrobials, 2024-08, Vol.23 (1), p.80-16 |
issn | 1476-0711 1476-0711 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_4bfa0dd6b27044e8af35bd2e63964d2c |
source | PubMed Central(OpenAccess); ProQuest - Publicly Available Content Database |
subjects | Anti-Bacterial Agents - pharmacology Antibacterial agents Antimicrobial resistance Care and treatment Clinical samples Complications and side effects Dosage and administration Drug resistance in microorganisms Drug Resistance, Bacterial Drug Resistance, Multiple, Bacterial Drug therapy Enterococcal infections Enterococcus faecalis Enterococcus faecalis - drug effects Global Health Gram-Positive Bacterial Infections - drug therapy Gram-Positive Bacterial Infections - epidemiology Gram-Positive Bacterial Infections - microbiology Hospital patients Humans Microbial Sensitivity Tests Patient outcomes Prevention Review Systematic review and meta-analysis |
title | Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T10%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Global%20status%20of%20antimicrobial%20resistance%20in%20clinical%20Enterococcus%20faecalis%20isolates:%20systematic%20review%20and%20meta-analysis&rft.jtitle=Annals%20of%20clinical%20microbiology%20and%20antimicrobials&rft.au=Guan,%20Lingbo&rft.date=2024-08-24&rft.volume=23&rft.issue=1&rft.spage=80&rft.epage=16&rft.pages=80-16&rft.issn=1476-0711&rft.eissn=1476-0711&rft_id=info:doi/10.1186/s12941-024-00728-w&rft_dat=%3Cgale_doaj_%3EA808371459%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d330t-34cca3bf019cb54f1efd7f4e3ce486f42ae21ead3c3b0b6c5f55ea5b7fdde76e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3097149127&rft_id=info:pmid/39182092&rft_galeid=A808371459&rfr_iscdi=true |